profit from every $100 of sales.
$0$100
Baxter International
$25.74-2.28% today
+37.6% in 1 year
1-year low $15.801-year high $28.35
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Baxter International sold, what it kept, and what it did with the cash.
Sales went from $10.1 billion in 2022 to $11.2 billion in 2025, with -$957 million of profit last year.
SalesProfit
Baxter International handed back more cash to shareholders than it generated last year.
$348M
Free cash flow 2025$323M
Bought back its own shares–
Paid as dividends$348M
Cash vs. debt$2.0B vs. $9.8B
Baxter International vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Baxter International | No profit yet | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.0× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 The Cooper Companies | 31.5× · Expensive |
AI analysis
An AI analyst reads Baxter International's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 11,673 | 12,146 | 10,057 | 10,360 | 10,636 | 11,244 | |
| 4,587 | 4,720 | 3,549 | 4,150 | 3,984 | 3,379 | |
| – | – | -33 | 707 | 439 | 177 | |
| 2,268 | 2,190 | -1,763 | 1,734 | 1,116 | 766 | |
| 1,102 | 1,284 | -2,433 | 2,656 | -649 | -957 | |
| 2.13 | 2.53 | -4.83 | 5.25 | -1.27 | -1.87 | |
| 39.3% | 38.9% | 35.3% | 40.1% | 37.5% | 30.1% | |
| – | – | -0.3% | 6.8% | 4.1% | 1.6% | |
| 9.4% | 10.6% | -24.2% | 25.6% | -6.1% | -8.5% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 20,019 | 33,521 | 28,287 | 28,276 | 25,782 | 20,055 |
| Cash | 3,730 | 2,951 | 1,718 | 3,078 | 1,764 | 1,966 |
| Total debt | 6,804 | 18,310 | 17,203 | 14,113 | 13,449 | 9,780 |
| Total liabilities | 11,293 | 24,400 | 22,392 | 19,808 | 18,758 | 13,953 |
| 8,689 | 9,077 | 5,833 | 8,402 | 6,964 | 6,129 | |
| 517 | 508 | 504 | 506 | 510 | 513 | |
| 7.4% | 3.8% | -9.7% | 2.6% | 0.5% | -1.1% | |
| 12.7% | 14.1% | -41.7% | 31.6% | -9.3% | -15.6% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1,868 | 2,222 | 1,211 | 1,726 | 1,019 | 845 | |
| 709 | 691 | 635 | 436 | 460 | 522 | |
| 1,159 | 1,531 | 576 | 1,290 | 559 | 323 | |
| Dividends paid | 473 | 530 | 573 | 586 | 590 | 348 |
| 500 | 600 | 32 | 0 | 0 | – | |
| 130 | 146 | 140 | 115 | 114 | 117 |
Valuation
- –
- 13.4×
- –
- 1.5×
- 1.2×
- 41.2×
- 27.6×
- 2.4%
- -7.2%
- 2.0%
Profitability
- 30.1%
- 1.6%
- -8.5%
- 6.6%
- -1.8%
- -0.6%
- -16.4%
- -5.5%
- -1.9%
- 4.6%
Growth
- −0.7%
- –
- −42.2%
- −11.4%
- +0.5%
Financial health
- 10.3×
- 1.60
- 48.8%
- -1.1×
- 1.85
- 1.23
- 0.57
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 33%of 952
Bottom 30%of 883
Bottom 14%of 870
Top 39%of 985
What analysts expect
- Average price target
- $20.00
- Range
- $15.00 – $27.00
- 7 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | 0.36 | 0.31 | +16.1% |
| Feb 12, 2026 | 0.44 | 0.53 | −17.0% |
| Oct 30, 2025 | 0.69 | 0.60 | +15.0% |
| Jul 31, 2025 | 0.59 | 0.60 | −1.7% |
| May 1, 2025 | 0.55 | 0.48 | +13.8% |
| Feb 20, 2025 | 0.58 | 0.53 | +9.8% |
| Nov 8, 2024 | 0.80 | 0.78 | +2.6% |
| Aug 6, 2024 | 0.68 | 0.66 | +2.7% |
2.0%of the share price, paid each year
On $1,000 invested$20a year at today's yield, before tax
−11.4%2020 to 2025
Raised–not every year
Paid per share, each year
$0.79 in 2015 → $0.52 in 2025
How safe it looks
-24.2% of its profit
Room to growStretchedMore than it earns: 107.7%
News
Should You Buy Baxter Stock For Its Cash?Yahoo Finance · Nov 3, 2026Baxter names John Rogers as CFOSeeking Alpha · Aug 19, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
14No pass
Benjamin Graham
40No pass
Philip Fisher
22No pass
Peter Lynch
13No pass
Joel Greenblatt
0No pass
Charlie Munger
16No pass
Terry Smith
12No pass
Questions about Baxter International
Is Baxter International a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Baxter International AI analysis
What does Baxter International do?
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. It is in Medical - Instruments & Supplies, based in Deerfield, IL, United States, with 37,500 employees.
Does Baxter International pay a dividend?
Yes. At today's price the dividend is 2.0% a year. In 2025 it paid out $348 million in dividends.
Is Baxter International stock halal?
No. Baxter International does not pass our halal screen: its debt is 73% of its market value, at or above the 33% limit. How we check
How has Baxter International stock done over the past year?
Up 37.6% over the past twelve months, to $25.74. It traded between $15.80 and $28.35 and is 9.2% below its high.
Who are Baxter International's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and The Cooper Companies. The peers table on this page compares their profit, growth and price with Baxter International's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.